Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.57 |
| ▸ | TDP2 | O95551 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596854 | 0.90 | KIF11 (0.47) | KIF11TDP2GRM2PDE3BPDE3A | |
| SCHEMBL4596446 | 0.80 | KIF11 (0.43) | KIF11TDP2PDE3BPDE3AAKT1 | |
| SCHEMBL1903306 | 0.74 | KIF11 (0.80) | KIF11TDP2GRM2PDE3BPDE3A | |
| SCHEMBL1396616 | 0.73 | KIF11 (1.00) | KIF11TDP2PDE3BPDE3AAKT1 | |
| SCHEMBL4596430 | 0.72 | KIF11 (0.59) | KIF11TDP2PDE3BPDE3A | |
| SCHEMBL11412815 | 0.72 | AHR (0.49) | PDE3BPDE3ACA9CA12 | |
| SCHEMBL4595139 | 0.71 | KIF11 (0.62) | KIF11TDP2GRM2PDE3BPDE3A | |
| SCHEMBL4596305 | 0.71 | KIF11 (0.62) | KIF11TDP2GRM2PDE3BPDE3A | |
| SCHEMBL4596362 | 0.70 | KIF11 (0.61) | KIF11TDP2PDE3BPDE3A | |
| SCHEMBL9684182 | 0.70 | PGR (0.36) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | KIF11 562/4885TDP2 1033/4885GRM2 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.